Belpointe Asset Management LLC bought a new stake in shares of Amedisys, Inc. (NASDAQ:AMED – Get Rating) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 678 shares of the health services provider’s stock, valued at approximately $57,000.
A number of other institutional investors have also recently made changes to their positions in AMED. First Trust Advisors LP boosted its stake in Amedisys by 54.0% during the third quarter. First Trust Advisors LP now owns 182,539 shares of the health services provider’s stock worth $17,668,000 after buying an additional 64,019 shares during the last quarter. Benjamin Edwards Inc. grew its holdings in shares of Amedisys by 18.9% in the fourth quarter. Benjamin Edwards Inc. now owns 879 shares of the health services provider’s stock valued at $73,000 after purchasing an additional 140 shares during the period. State Board of Administration of Florida Retirement System increased its position in Amedisys by 2.5% during the third quarter. State Board of Administration of Florida Retirement System now owns 39,053 shares of the health services provider’s stock worth $3,780,000 after purchasing an additional 970 shares during the last quarter. Fort Washington Investment Advisors Inc. OH raised its stake in Amedisys by 54.0% during the fourth quarter. Fort Washington Investment Advisors Inc. OH now owns 142,850 shares of the health services provider’s stock worth $11,934,000 after purchasing an additional 50,090 shares during the period. Finally, Counterpoint Mutual Funds LLC acquired a new position in Amedisys in the 4th quarter valued at about $107,000. Hedge funds and other institutional investors own 96.17% of the company’s stock.
Insider Buying and Selling at Amedisys
In other news, insider Michael Paul North sold 5,908 shares of the company’s stock in a transaction on Friday, March 3rd. The shares were sold at an average price of $86.43, for a total transaction of $510,628.44. Following the transaction, the insider now directly owns 4,164 shares of the company’s stock, valued at approximately $359,894.52. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. 2.10% of the stock is owned by corporate insiders.
Analysts Set New Price Targets
Amedisys Stock Down 0.3 %
AMED stock opened at $79.13 on Tuesday. The company’s 50 day moving average is $76.75 and its two-hundred day moving average is $84.37. Amedisys, Inc. has a twelve month low of $69.36 and a twelve month high of $131.32. The company has a current ratio of 1.15, a quick ratio of 1.15 and a debt-to-equity ratio of 0.33. The stock has a market cap of $2.58 billion, a P/E ratio of 23.00, a PEG ratio of 2.22 and a beta of 1.02.
Amedisys (NASDAQ:AMED – Get Rating) last released its earnings results on Thursday, May 4th. The health services provider reported $1.00 EPS for the quarter, topping the consensus estimate of $0.86 by $0.14. The company had revenue of $556.39 million during the quarter, compared to analysts’ expectations of $558.98 million. Amedisys had a net margin of 5.02% and a return on equity of 14.35%. The business’s revenue was up 2.0% on a year-over-year basis. During the same quarter last year, the business earned $1.23 EPS. Research analysts expect that Amedisys, Inc. will post 4.25 earnings per share for the current fiscal year.
Amedisys, Inc engages in the provision of healthcare services. It operates through the following business segments: Home Health, Hospice, Personal Care, and High Acuity Care. The Home Health segment delivers services in the homes of individuals who may be recovering from an illness, injury, or surgery.
- Get a free copy of the StockNews.com research report on Amedisys (AMED)
- monday.com Surges on Price and Volume after Blowout Results
- Can Ryanair Stock Fly Above Resistance Levels, What Earnings Show
- All Aboard! The Sell-Side Has Railroads In Reversal
- Is There Value Left in Lyft Stock?
- Everything About ZIM Integrated Screams Undervaluation
Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.